Aurobindo Pharma, MSN Labs seek DCGI nod for Phase-III trials of Molnupiravir

The SEC opined that the firms should submit the same in writing to CDSCO for further consideration.


Last Updated on October 11, 2021 by The Health Master

Two Indian pharmaceutical companies have sought permission from India’s drug regulator to continue phase III trials on antiviral drug molnupiravir in mild C-19 patient. US firm Merck & Co’s experimental antiviral drug molnupiravir is touted to become first antiviral drug to treat C-19.

Last week, Aurobindo Pharma and MSN Laboratories presented the interim clinical trial data in moderate patients before the the Subject subject expert committee (SEC) — the expert panel under the Drug Controller General of India (DCGI).

The SEC advises the drug regulator on applications seeking approvals for new vaccines, drugs and clinical trials in India.

In a meeting held on October 4, both the companies said that they “they want to discontinue phase III trial in moderate C-19 patients and continue the phase III trial in mild C-19 patients”, as per the minutes of the meeting. ET has seen the minutes of the SEC meeting.

The SEC opined that the firms should submit the same in writing to CDSCO for further consideration.

According to Merck Molnupiravir reduces the risk of hospitalisation and death by 50% in an interim trial. The company also said that they would seek emergency approval from the US regulator.

Merck has also entered into voluntary licensing agreements with at many Indian drug companies including Dr Reddy’s Laboratories, Cipla, Sun Pharma, Emcure Pharmaceuticals, Aurobindo Pharma, among others.

DCGI gives permission to conduct Phase III trial for two-dose C-19 vaccine

DCGI’s nod to AstraZeneca to import, market Selumetinib Capsules

DCGI nod to BDR Pharma for drug to treat various infections

DCGI approves Clinical Trial of MESOCEL therapy to treat COVID

Sputnik Single Dose Vaccine gets DCGI nod for Phase-III trials in India

DCGI grants EUA to Truenat for Nipah virus tests in India

Recommendation of restriction on import of IPA used by Pharma Industry

Licensing process to ASU drug manufacturers made Paperless

Dedicated chapter on Medical Devices should be included in Pharmacy Course:…

Generic medicines are cheaper as compared to branded and equally effective

USFDA gives nod to Drug to treat Rare Autoimmune Disease

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
YouTube Icon

Enter your email address:

Delivered by FeedBurner